p300/CBP bromodomain inhibitor

PD observed in serial biopsies from Ph. I

50 mg QD, 3-d-on-4-off; origin not discussed

Cancer Discovery, Jan. 11, 2021

ICR / Royal Marsden / CellCentric, UK

Chemical structure of molecule CCS1477 Bromodomain inhibitor

The CellCentric p300/CBP inhibitor, CCS1477, is an orally available drug in early development for advanced prostate cancer, and is structurally distinct from the p300/CBP inhibitor we covered in Apr.…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: